The NFE2L2 Knockout A549 Cell Line is a CRISPR/Cas9-edited knockout cell line derived from human A549 lung adenocarcinoma epithelial cells. This product provides a genetically defined loss-of-function model for studying NFE2L2, which encodes transcription factor NRF2, the master regulator of the antioxidant response. CRISPR/Cas9-mediated gene disruption eliminates functional NFE2L2, enabling dissection of NRF2-dependent signaling and cytoprotective mechanisms in a disease-relevant cellular context. The knockout cell line is suitable for a broad range of functional assays and comparative studies with parental A549 cells.
The parental A549 cell line was established from human lung adenocarcinoma and is widely used as an in vitro model for lung epithelial biology, cancer research, and respiratory diseases. A549 cells retain characteristics of alveolar type II epithelial cells and exhibit robust adherence and ease of culture. Their relevance to non-small cell lung cancer (NSCLC) makes them a standard platform for investigating tumor biology, drug responses, and oxidative stress pathways. The NFE2L2 knockout variant extends this utility by allowing direct interrogation of NRF2??s role in lung adenocarcinoma pathology, chemoresistance, and redox homeostasis.
NFE2L2 functions as a pivotal transcription factor orchestrating cellular defense against oxidative and electrophilic insults. Under basal conditions, KEAP1 sequesters NFE2L2 in the cytoplasm, mediating its ubiquitination and proteasomal degradation. Upon oxidative stress, KEAP1 is inhibited, allowing NFE2L2 to stabilize, translocate to the nucleus, and heterodimerize with small MAF proteins. The complex binds antioxidant response elements (AREs) to drive expression of cytoprotective genes, including NQO1, HMOX1, GCLC, GCLM, and TXNRD1. NFE2L2 activity is modulated by upstream kinases (PKC, PI3K/AKT, MAPK) and cofactors such as CBP/p300 and BACH1, positioning it at the nexus of redox control, drug metabolism, and ferroptosis.
In lung adenocarcinoma, dysregulation of the KEAP1?CNFE2L2 pathway is common due to mutations or epigenetic changes, leading to constitutive NRF2 activation that promotes survival, chemoresistance, and metabolic reprogramming. The NFE2L2 Knockout A549 Cell Line enables dissection of how NRF2 loss impacts cancer cell viability, drug sensitivity, and ferroptosis susceptibility. Eliminating NRF2??s protective transcriptional program allows researchers to evaluate dependence on antioxidant defenses, study oxidative damage consequences, and identify synthetic lethal interactions. This model is valuable for investigating mechanisms of resistance to platinum-based chemotherapies or targeted agents in NSCLC.
Research applications include mechanistic studies of the KEAP1?CNFE2L2 pathway, oxidative stress response profiling, ferroptosis induction, and chemoresistance screens. Commonly used assays include western blotting, RT-qPCR, ROS measurement, cell viability under oxidative challenge, drug sensitivity testing, ARE luciferase reporter assays, and RNA-seq. These approaches facilitate dissection of redox signaling and identification of novel NRF2 targets. For further details, please contact Ascent Research.
